NeuroSense Therapeutics Receives Nasdaq Notifications on Compliance Issues

Company has until September 2026 to regain compliance with minimum bid price and market value requirements

Apr. 3, 2026 at 2:36pm

Got story updates? Submit your updates here. ›

A minimalist studio still life photograph featuring a stack of pill bottles, a syringe, and a petri dish arranged on a clean, grey background, conceptually representing the challenges of drug development and market compliance facing the biotech industry.As a biotech firm navigates regulatory hurdles, its struggle to maintain a Nasdaq listing reflects the delicate balance between innovation and financial viability in the pharmaceutical industry.Cambridge Today

NeuroSense Therapeutics, a clinical-stage biotech company, announced that it received two notification letters from Nasdaq indicating the company is not in compliance with certain continued listing requirements. The company has until September 29, 2026 to regain compliance with the minimum bid price of $1.00 per share and the minimum market value of listed securities of $35 million. NeuroSense is actively evaluating actions to regain compliance while focusing on initiatives that support long-term shareholder value.

Why it matters

Maintaining Nasdaq listing is crucial for NeuroSense to access public capital markets and continue funding its late-stage clinical trials for treatments of severe neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's. The notifications highlight the company's financial and operational challenges, which could impact investor confidence if not addressed in a timely manner.

The details

The first notification letter indicated NeuroSense's ordinary share price closed below $1.00 per share for 30 consecutive business days. The second notification said the company's market value of listed securities fell below the $35 million minimum requirement over the same period. NeuroSense's shares and warrants will continue trading on Nasdaq during the 180-day compliance period.

  • From February 18, 2026 through March 31, 2026, NeuroSense's ordinary share price closed below $1.00 per share for 30 consecutive business days.
  • Over the same period, NeuroSense's market value of listed securities fell below the $35 million minimum requirement for 30 consecutive business days.
  • NeuroSense has until September 29, 2026 to regain compliance with both the minimum bid price and market value requirements.

The players

NeuroSense Therapeutics Ltd.

A late-stage clinical biotechnology company developing treatments for severe neurodegenerative diseases.

Nasdaq

The stock exchange that NeuroSense's ordinary shares and warrants trade on.

Got photos? Submit your photos here. ›

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Maintaining a Nasdaq listing is crucial for NeuroSense to access public capital markets and continue funding its late-stage clinical trials. The notifications highlight the company's financial and operational challenges, which could impact investor confidence if not addressed in a timely manner.